Companies › Mineralys Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| lorundrostat Aldosterone synthase inhibitor | CYP11B2 | Phase 3 | Hypertension | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05968430 | lorundrostat | Phase 3 | Hypertension | Cardiovascular | May 2027 |
Cash of $101m on 2026-09-30; operating cash outflow about $154m a year; runway about 8 months at that burn, to May 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Gossamer Bio USA Grace Therapeutics Trust Bio-sonics Liquidia Technologies EVD Pharmacy and Medical Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.